相关实验视频

Updated: Jul 6, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

在转移性固体癌症患者 (Abscopal 5001试验) 中进行多重瘤内免疫疗法 (MITI) 的首次人体II期临床试验

David G Bostwick¹, Melanie M Wilk¹, Brian R Bostwick¹

¹Rampart Health, 4724 Lake Calabay Drive, Orlando, FL 32837, USA.

|September 27, 2025

概括

多重瘤内免疫疗法 (MITI) 结合了冷和RPT-01-5001,在转移性癌症中显示出77%的疾病控制率. 这种新的方法证明了31%的腹膜效应,为那些标准疗法失败的患者提供了新的治疗选择.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
癌症移除癌症移除

背景情况:

对于将内免疫疗法与癌症切除技术相结合的理解有限.
在对标准疗法耐药的转移性固体癌症中需要新的治疗方法.

研究的目的:

评估多重内免疫疗法 (MITI) 在转移性固体癌症患者的安全性和有效性.
在II期试验中评估结合RPT-01-5001 (检查点抑制剂和环胺) 的冷.

主要方法:

第二期试验 (Abscopal 5001) 涉及13名转移性固体癌症患者.
MITI程序:CT指导的冷化,然后是RPT-01-5001的内注射,然后是低剂量环胺.
基于iRECIST标准的GM-CSF给药和治疗重复,根据病理发现进行修改.

主要成果:

高可行性和安全性,具有可管理的不良事件 (级别1-2).
实现了77%的疾病控制率 (iCR:7.7%, iPR:30.8%, iSD:38.5%).
观察到31%的腹膜效应,包括在一些患者中完全消除远程转移.

结论:

MITI与RPT-01-5001是对转移性癌症的安全和可行的治疗方法.
组合疗法证明了显著的疾病控制,并诱导了显著的腹效应.
这种方法为没有对传统治疗反应的晚期癌症提供了一个有希望的治疗策略.

关键词:

这是一种PD-1抑制剂.这是一个abscopal abscopal.癌症癌症癌症癌症癌症检查点抑制剂检查点抑制剂临床试验临床试验临床试验临床试验临床试验免疫疗法免疫疗法在口内入口.发生转移的转移.第二阶段第二阶段.这是一个前性的前性.

更多相关视频

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.